Division of Diabetes and Nutrition at RARiS, Tohoku University,Ā Japan
š
Dr. Katsunori Nonogaki is a distinguished professor and clinical specialist in diabetes and internal medicine, holding extensive expertise in lifestyle medicine and diabetes research. He obtained his MD in Japan in 1987, followed by a PhD from Nagoya University Graduate School of Medicine in 1993. His postdoctoral training included positions at UCSF and The Scripps Research Institute, where he focused on metabolism and neuropharmacology. Dr. Nonogaki has held key academic roles at prestigious institutions, including the University of Tokyo and Tohoku University, where he has been a professor since 2008.
Professional ProfileĀ
š Work Experience & Teaching
Dr. Nonogaki has a long-standing academic career, beginning as a lecturer at the University of Tokyo before joining Tohoku University in various professorial roles. His teaching experience spans undergraduate to postgraduate levels, where he mentors future leaders in diabetes research and metabolic health.
šļø Skills, Awards, and Honors
Dr. Nonogaki is highly skilled in molecular nutrition, metabolic diseases, and translational research. He has served as the Chief of the Laboratory of Molecular Nutrition and is recognized for his contributions to diabetes research, earning several awards in this domain. He has also made impactful contributions to scientific literature, serving on the editorial boards of key journals such as Frontiers in Endocrinology and Diabetes Research and Clinical Practice.
š Memberships & Professional Involvement
His professional involvement extends to numerous editorial roles, including Topic Editor and Associate Editor in leading journals. Dr. Nonogaki is a highly regarded member of the international diabetes research community, where he actively contributes to advancements in metabolic health and diabetes management.
Research Focus
Xiaofengās research is centered on entrepreneurial behavior, project selection, and risk assessment. He has proposed a three-stage theory for project selection and developed a dynamic measurement model for entrepreneurial risks. His work has practical implications, particularly in the evaluation of risks in family farms and entrepreneurship education. His 65 published journal articles and various patents further underscore his contributions to the field.
Publications :Ā
“The GLP-1 Receptor Agonist Liraglutide Decreases Primary Bile Acids and Serotonin in the Colon Independently of Feeding in Mice”
Year: 2024
Journal: International Journal of Molecular Sciences